Summary
The interaction of the new beta-receptor antagonist tertatolol with rifampicin and ranitidine was investigated in ten patients with arterial hypertension (WHO stages I–II). They were treated orally with a single dose of tertatolol 5 mg alone and, after randomized allocation, with ranitidine 150 mg twice daily or rifampicin 600 mg once daily for 1 week each (tertatolol 5 mg was concurrently administered on the seventh day of the treatment phases). Following each therapeutic phase, circadian blood pressure values as well as kinetic parameters were obtained. On treatment with tertatolol alone, maximum plasma concentrations were 123.7 ±32.4 ng/ml\((\bar X \pm SD)\) and were reached after 1.95±1.77 hours. The tertatolol elimination half-life was 9.0±7.1 hours. Coadministration of ranitidine did not significantly alter the kinetic parameters and antihypertensive effect of tertatolol. Rifampicin, however, decreased the maximum plasma levels of tertatolol to 80.6±18.5 ng/ml and markedly shortened the elimination half-life to 3.4±2.6 hours (p<0.01 compared with tertatolol alone). Urinary excretion of parent tertatolol and unchanged 4-hydroxy tertatolol was decreased under rifampicin, and a tendency to a reduction in the effect of tertatolol on circadian blood pressure values was observed. Twenty-four hours after administration, the heart rate in those patients on tertatolol alone (68±6 beats/min) was lower than in those on tertatolol plus rifampicin (74±7 beats/min). In conclusion, a pronounced pharmacokinetic interaction, with a limited consequence in terms of pharmacodynamic effects, was found in the present study when tertatolol was administered with rifampicin, but not with ranitidine.
Similar content being viewed by others
References
Blasi de A, Lipartiti M, Pirone F, et al. Reduction of betaadrenergic receptors by tertatolol. An additional mechanism for beta-adrenergic blockade.Clin Pharmacol Ther 1986;39:245–254.
Verbeuren TJ, Laekeman G, Majchrowicz BB, et al. Effects of tertatolol on post-and prejunctional beta-adrenoceptors.J Pharmacol Exp Ther 1985;233:801–809.
Walker BR, Erickson AL, Prost JF, et al. Cardiovascular and renal effects of the β-blocker SE 2395 in conscious normotensive dogs.J Cardiovasc Pharmacol 1985;7:1193–1197.
Laubie M, Prost JF, Rochat C. Renal hemodynamic effects of tertatolol compared with those of propranolol in the conscious dog.Am J Nephrol 1986;6(Suppl 2):20–24.
Leeman M, Naeije R, Degaute JP, et al. Acute central and renal haemodynamic responses to tertatolol and propranolol in patients with arterial hypertension following head injury.J Hypertens 1986;4:581–587.
Paillard F, Lantz B, Leviel F, et al. Renal hemodynamic effects of tertatolol in essential hypertension.Am J Nephrol 1986;6(Suppl 2):40–44.
Campbell DB, Chignon JC, Devissaguet JPh. Biodisposition of tertatolol in man: A review.Am J Nephrol 1986;6(Suppl 2): 61–68.
Staveris S, Blaise P, Efthymiopoulos C, et al. Quantitative determination of tertatolol in biological fluids by GC-MS.J Chromatogr Biomed Applicat 1985;339:97–103.
Herman RJ, Nakamura K, Wilkinson GR, et al. Induction of propranolol metabolism in man by rifampicin.Pharmacology 1982;24:191–189.
Bennett PN, John VA, Whitmarsh VB. Effect of rifampicin on metoprolol and antipyrine kinetics.Br J Clin Pharmacol 1982;13:387–391.
Kirch W, Klingmann I, et al. Interaction of bisoprolol with cimetidine and rifampicin.Eur J Clin Pharmacol 1986;31:59–62.
Roy AK, Cuda MP, Levine RA, Induction of theophylline toxicity and inhibition of clearance rates by ranitidine.Am J Med 1988;85:525–527.
Fernandez E, Melewicz FM. Ranitidine and theophylline.Ann Intern Med 1984;100:459–460.
Elwood JR, Hildebrand PJ, Dundee JW, et al. Ranitidine influences uptake of oral midazolam.Br J Clin Pharmacol 1983;15:743–745.
Kirch W, Hoensch H, Janisch HD. Interactions and noninteractions with ranitidine.Clin Pharmacokin 1984;9:493–502.
Kirch W, Janisch HD, Heidemann H, et al. Der Einfluß von Cimetidin und Ranitidin auf Pharmakokinetik und antihypertensiven Effekt von. Nifedipin.Dtsch Med Wschr 1984;109:1223–1231.
McWalter RS, elDebani AH, Feely J, et al. Potentiation by ranitidine of the hypoglycaemic response to glipizide in diabetic patients.Br J Clin Pharmacol 1985;19:121–125.
Desmond PV, Mashford ML, Harman PJ, et al. Decreased oral warfarin clearance after ranitidine and cimetidine.Clin Pharmacol Ther 1984;35:338–341.
Robson RA, Wing LM, Miners JO, et al. The effect of ranitidine on the disposition of lignocaine.Br J Clin Pharmacol 1985;20:170–172.
Hoensch HP, Hutzel H, Kirch W, et al. Isolation of human hepatic microsomes and their inhibition by cimetidine and ranitidine.Eur J Clin Pharmacol 1985;29:199–203.
Somogyi A, Gugler R. Drug interactions with cimetidine.Clin Pharmacokin 1982;7:23–35.
Smith SR, Kendall MJ. Ranitidine versus cimetidine: A comparison of their potential to cause clinically important drug interaction.Clin Pharmacokin 1988;15:44–56.
Efthymiopoulos C, Staveris S, Weber F, et al. Simultaneous quantitative determination of tertatolol and its hydroxylated metabolite in human plasma and urine by gas chromatography-mass spectrometry.J Chromat Biomed Applicat 1987;421:360–366.
Francis RJ. Elsmos: An extended least squares modelling system in Fortran IV for mini or micro computer implementation.Comp Prog Biomed 1984;19:43–50.
Winer BJ. In:Statistical principles in experimental design. New York: McGraw-Hill, 1971.
Siegel S. In:Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, 1956:166–172.
Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance.Clin Pharmacol Ther 1975;18:377–390.
Branch RA, Herman RJ. Enzyme induction and ß-adrenergic receptor blocking drug.Br J Clin Pharmacol 1984;17:77S-84S.
Heagerty AM, Castleden CM, Patel L. Failure of ranitidine to interact with propranolol.Br Med J 1982;284–1304.
Spahn H, Mutschler E, Kirch W, et al. Influence of ranitidine on plasma metoprolol and atenolol concentrations.Br Med J 1983;286:1546–1547.
Kelly JG, Shanks RG, McDevitt, DG. Influence of ranitidine on plasma metoprolol concentrations.Br Med J 1983;287: 1218–1219.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirch, W., Milferstädt, S., Halabi, A. et al. Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. Cardiovasc Drug Ther 4, 487–491 (1990). https://doi.org/10.1007/BF01857758
Issue Date:
DOI: https://doi.org/10.1007/BF01857758